Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at NLS Pharmaceutics AG fell by 8.05m. Cash Flow from Financing totalled 1.63m or -- of revenues. In addition the company used 9.68m for operations while cash from investing was breakeven.
Cash flow per share | -0.3185 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.2724 |
---|---|
Tangible book value per share | -0.2724 |
More ▼
Balance sheet in USDView more
Current ratio | 0.2302 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼